LOMBARD MEDICAL TECHNOLOGIES PLC 
By ?
Lombard Medical Technologies PLC
("Lombard Medical" or the "Company")
AGM Results
London, UK, 23 May 2013 - Lombard Medical Technologies PLC (AIM:LMT), the specialist medical technology company focussed on innovative vascular products, announces thatat the Annual General Meeting held earlier today, all resolutions were passed by shareholders on a show of hands.
Full details of the proxy voting will be available, later today, on the Company's website at: www.lombardmedical.com
-Ends-
Enquiries:
Lombard Medical Technologies PLC | Tel: 01235 750800 |
Simon Hubbert, Chief Executive Officer | |
Ian Ardill, Chief Financial Officer | |
Canaccord Genuity Limited | Tel: 020 7523 8000 |
Lucy Tilley / Henry Fitzgerald O'Connor / Dr. Julian Feneley | |
FTI Consulting | |
Simon Conway / Susan Stuart / Victoria Foster Mitchell | Tel: 020 7831 3113 |
About Lombard Medical
Lombard Medical Technologies PLC (AIM: LMT), is a medical device company focused on device solutions for the $1.2 billion dollar per annum abdominal aortic aneurysm (AAA) repair market. AAAs are a balloon-like enlargement of the aorta which, if left untreated, may rupture and cause death. Approximately 4.5 million people are living with AAAs in the developed world and each year 600,000 new cases are diagnosed. The market for endovascular stent grafts for this application is expected to grow to $1.6 billion by 2015. The Company's lead product, Aorfix?, is an endovascular stent graft which has been specifically designed to solve the problems that exist in treating complex tortuous anatomy which is often present in advanced AAA disease. Aorfix? is currently being commercialised in the EU, and has been submitted to the FDA for approval in the U.S.
The Company is headquartered in Oxfordshire, with operations in Ayrshire and Phoenix, USA.
This information is provided by RNS
|
distributed by
|
